“DOSE OF REALITY” Big Pharma’s True Track Record Is A Hard Pill To Swallow: Part III

02-19-2019 Blog Posts

In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]

DOSE OF REALITY: Big Pharma’s True Track Record Is A Hard Pill To Swallow – Part II

02-18-2019 Blog Posts

In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend – and why their rhetoric rings hollow when measured against their companies’ track record. […]

DOSE OF REALITY: Big Pharma’s True Track Record Is A Hard Pill To Swallow – Part I

02-15-2019 Blog Posts

As bipartisan momentum to hold Big Pharma accountable and take action on out-of-control drug prices continues to build, the U.S. Senate Committee on Finance is scheduled to question the executives of seven major pharmaceutical manufacturers on February 26, 2019. In advance of the hearing, the second held by the committee on drug pricing this year, […]

What they’re Saying: Reactions to Congress’ Drug Pricing Hearings

02-2-2019 Blog Posts

On Tuesday, the U.S. House Oversight and Reform and Senate Finance Committees held their first hearings on drug pricing. The fact that the first hearings held in these committees were about skyrocketing drug prices sent a clear message to Big Pharma that Congress is ready to hold them accountable for their price-gouging tactics. Check out […]

THEY SAID IT! Drug Companies Have Been Warned

01-31-2019 Blog Posts

Drug Companies Have Been Warned: House & Senate Chairmen & Ranking Members Pledge To Work Together To Hold Big Pharma Accountable U.S. Senate Chairman Of The Committee On Finance Chuck Grassley: “You will hear many numbers describing the costs of prescription drugs.  Those numbers are impressive, but the stories I have heard from patients, doctors, […]

Second Opinion: R&D Is Not To Blame For Skyrocketing Drug Costs

01-17-2019 Blog Posts

The jig is up – a new report showsthat “the skyrocketing cost of many prescription drugs in the U.S. can be blamed primarily on price increases, not expensive new therapies or improvements in existing medications as drug companies frequently claim.” The new research, published in Health Affairs, shows that drugs are increasing at a rate faster than […]

Second Opinion: No, Big Pharma Is Not Changing

01-11-2019 Blog Posts

Right on cue, dozens of pharmaceutical companies rang in the new year by increasing hundreds of drug prices by up to 15 times the rate of inflation – despite the fact that their profits continue to far exceed spending on research and development.  In just one week: Allergan increased the price of two dozen drugs […]

Second Opinion: Big Pharma’s Back At It

12-3-2018 Blog Posts

If at first you don’t succeed try, try again.  That’s the old adage Big Pharma is sticking with this month in a last-ditch effort to make more money on the backs of patients and taxpayers. Here’s a quick backstory: Earlier this year, Congress took significant steps in the Bipartisan Budget Act of 2018 (BBA) to […]

It’s Time To Go To Work To Lower Prescription Drug Prices

11-12-2018 Blog Posts

Now that the midterms are over, it is now time for candidates to do what they promised voters if elected: enact real solutions that will rein in out-of-control drug prices. Across the country, skyrocketing drug prices became one of the most prominent issues on the campaign trail – and for good reason.  One-in-four Americans can’t […]

On Message: Big Pharma Executives Double Down On Monopolistic Business Strategy

11-6-2018 Blog Posts

Executives of three major drug manufacturers – Pfizer, Merck and AbbVie – are doubling down on three drivers of Big Pharma’s business strategy:   Price-Gouging: After agreeing to suspend price increases earlier this year, Pfizer CEO Ian Read told shareholders on the company’s Q3 earnings call that they’re going back to “business as normal” – i.e. […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.